Drug Trial Radar · NCT02207621
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Apr 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
756
Actual
Start
Jul 2014
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Aerie PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
Conditions
- Ocular Hypertension
- Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%Drug
1 drop once daily (QD), PM, OU
Timolol maleate Ophthalmic Solution 0.5% BIDDrug
1 drop BID, AM/PM, OU
PlaceboOther
1 drop QD, AM, OU
AR-13324 Ophthalmic Solution 0.02% BIDDrug
1 drop BID, AM/PM, OU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP)Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerie Pharmaceuticals
Bedminster, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.